Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03199846 · ClinicalTrials.gov registry record

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

A clinical trial, sponsored by Bristol-Myers Squibb.

Completed
Registry status
650
Enrollment target

NCT03199846 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 650 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03199846 has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
650 participants
Enrollment target

Study Summary

This study will collect real-world data from advanced melanoma diagnosis through most recent visit and data sourced from patient medical records following a 2-part study design consisting of a random sample (Part 1) and an oversample (Part 2).

Interventions

  • OTHER Non-Interventional

Trial Details

FieldValue
Enrollment Target 650 participants
Start Date 2016-10-25
Est. Completion 2017-12-31

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT03199846

The ClinicalTrials.gov registry entry for NCT03199846 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 650 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.

NCT03199846 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03199846 about?

NCT03199846 is a clinical study titled "Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States". This study will collect real-world data from advanced melanoma diagnosis through most recent visit and data sourced from patient medical records following a 2-part study design consisting of a random sample (Part 1) and an oversample (Part 2).

What is the current status of trial NCT03199846?

This trial is currently completed. The enrollment target is 650 participants. The study started on 2016-10-25. Estimated completion is 2017-12-31.

What interventions are being tested in trial NCT03199846?

The interventions under investigation include: Non-Interventional (OTHER).

Who is sponsoring clinical trial NCT03199846?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.